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Although the role of class I and class II MHC in adaptive
immunity against microbial pathogens is clear, the partici-
pation of nonpolymorphic MHC molecules in host defense
remains less well defined. Roles for murine class I MHC
molecule Qa-2 and class Ib molecule H2-M3 have been
suggested (1–3), and accumulating data have prompted
speculation that CD1 family members may be important in
immunity against pathogenic mycobacteria and parasites
(4). In this issue, Spada et al. report the restriction of at least
 
some human V
 
g
 
2/V
 
d
 
1 T cells, the most common tissue
 
g
 
/
 
d
 
 T cells, by CD1c (5). Like other populations of CD1-
restricted T cells, as discussed further below, the CD1c-
restricted cells were autoreactive in vitro. These cells pro-
 
duced IFN-
 
g
 
, but not IL-4, and displayed cytotoxicity
 
against CD1c
 
1
 
 targets, leading the authors to speculate that
such cells might be involved in innate host defense against
prevalent pathogens. In this way, 
 
g
 
/
 
d
 
 and other CD1-
restricted T cells would represent unique small populations
of lymphocytes that have been evolutionarily maintained
because of their capacity to react rapidly to microbes.
However, pathogens are clever, and an equally plausible
hypothesis is that pathogens have exploited unusual T cell
populations that exist for reasons different than immunity.
Indeed, based on comparisons with other nonpolymorphic
MHC molecules, we suspect that the primary role of such
molecules may not entail immunity to infectious organ-
isms, but may rather underlie a basic mechanism for the
maintenance of cell and tissue homeostasis. The ancient
process by which MHC molecules sample distinct cellular
compartments may have been later coopted by classical
MHC molecules to mediate protective immunity at the
time of acquisition of bacteria-derived recombination acti-
vating gene (RAG) transposases and the establishment of a
system for adaptive immunity (6). By this alternate hypoth-
esis, mycobacteria uniquely exploit the underlying biologi-
cal processes mediated by CD1.
 
The CD1 Family: Genomic Organization and Structure
 
The CD1 family comprises a heterogeneous group of
 
b
 
2-microglobulin (
 
b
 
2m)-associated transmembrane pro-
teins that bear a strong structural resemblance to the classic
MHC antigens (4). However, in contrast to the latter, CD1
genes are relatively nonpolymorphic, and are encoded by
genes distant from the classic MHC loci. In humans, five
CD1 genes on chromosome 1 are known to encode four
proteins, designated CD1a, b, c, and d; CD1e may repre-
sent a pseudogene. The CD1 family is further subdivided
into group 1, comprising CD1a, b, and c, and group 2,
comprising CD1d, based on sequence and functional ho-
mology. In the mouse, an ancient translocation likely re-
sulted in the loss of the group 1 genes (7); only CD1d1 and
a duplicated gene, CD1d2, remain on the syntenic region
of chromosome 3.
Crystallographic analysis of mouse CD1d1 confirmed the
preservation of domain organization between this molecule
and the structure of classic MHC (8). As with class I MHC,
an externally disposed binding cleft formed by an eight-
stranded antiparallel 
 
b
 
-sheet floor bounded by the 
 
a
 
1 and
 
a
 
2 helices provided evidence for a molecule involved in
ligand display. However, in contrast to the sequential small
binding pockets that accommodate individual amino acids
of the peptide backbone in classic MHC, the CD1d1 cleft
consisted of two large pockets lined with hydrophobic resi-
dues. Although capable of binding long, highly hydropho-
bic peptides (9), it is likely that the unique structure under-
lies the capacity of CD1 to present lipid ligands. The
functionally interchangeable nature of mouse and human
CD1d molecules, such that mouse CD1 can present to hu-
man CD1-restricted T cells and vice versa (10), suggests
that the human CD1d structure will be similar.
 
Recognition of CD1 by T Cells Bearing Limited TCR Diversity
 
The description of CD1-restricted tumor cytotoxicity by
CD4
 
2
 
CD8
 
2
 
 
 
a
 
/
 
b
 
 or 
 
g
 
/
 
d
 
 human T cells provided the initial
hypothesis that CD1 might subserve an immune function
(11–13). Shortly thereafter, murine NK1.1
 
1
 
 T cells were
demonstrated to be CD1 restricted (14).
The unusual nature of the TCRs that recognize these
nonpolymorphic CD1 molecules suggested limited ligand
diversity. Best characterized are CD1d-restricted TCRs ex-
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pressed on NK1.1 T cells from mice and humans (15). In
mice, these double negative or CD4
 
1
 
 T cells express an in-
variant V
 
a
 
14J
 
a
 
281 TCR paired with a highly restricted
set of V
 
b
 
 chains, usually V
 
b
 
8, V
 
b
 
7, or V
 
b
 
2, that may re-
flect tissue-specific expansion or homing. Strikingly, CD1d-
restricted human T cells use essentially the same TCR, the
homologous V
 
a
 
24J
 
a
 
Q/V
 
b
 
11 TCR. In mice, these cells co-
express typical NK lineage markers and undergo thymic se-
lection by CD1-expressing, bone marrow–derived cortical
thymocytes (16). A second subset of CD1d-restricted cells
does not express NK lineage markers or the invariant V
 
a
 
14
TCR, although the expressed TCRs reveal highly restricted
V
 
a
 
J
 
a
 
 usage, frequently paired with V
 
b
 
8 (17).
Although 
 
a
 
/
 
b
 
 TCR usage by T cells restricted by CD1
antigens other than CD1d remains less well studied, emerg-
ing evidence suggests that these also will show limited di-
versity. In humans, such cells are typically double negative
or CD8
 
a
 
/
 
a
 
1
 
. Expressed TCRs from such cells displayed
limited numbers of TCR 
 
a
 
 chains (V
 
a
 
4, V
 
a
 
7, V
 
a
 
19, and
V
 
a
 
24) that were shared among individuals with no identity
at classic MHC molecules (18). The most prevalent (hu-
man V
 
a
 
7S2, J
 
a
 
33, and V
 
b
 
2S1 or V
 
b
 
13) were restricted by
CD1b, and strikingly were completely homologous to TCRs
on double negative T cells from mice and cattle (19). In
mice, such cells were present in CD1d-deficient but not
 
b
 
2m-deficient mice, and the selecting ligand remains un-
known. The report by Spada et al. in this issue (5) extends
the concept of limited diversity to human CD1c-restricted
T cells. Although extrapolated from relatively few exam-
ples, these cells all expressed V
 
g
 
2/V
 
d
 
1 TCRs with or
without CD8
 
a
 
/
 
a
 
, and reacted to CD1c presented by a va-
riety of cell types.
CD1-restricted 
 
a
 
/
 
b
 
 and 
 
g
 
/
 
d
 
 T cells are present in low
numbers at birth, and then rise progressively in blood and
select tissues—liver, bone marrow, and spleen—to consti-
tute from 1 to 20% of cells, a prevalence not unlike NK
cells. In humans, but not mice or rats, they can express
CD8
 
a
 
/
 
a
 
, which may reflect their activation status (20).
These cells display a memory effector antigen profile on
their surface that is consistent with their capacity to rapidly
secrete large amounts of cytokines or to generate cytotox-
icity after TCR ligation (4, 15). Such instantaneous effector
capacity distinguishes these cells compared with main-
stream naive CD4 and CD8 T lymphocytes. Although the
V
 
g
 
2/V
 
d
 
1 T cells described by Spada et al. (5) demonstrated
cytotoxicity and a type 1 cytokine profile, such findings need
to be tempered by the observation that these cells were se-
lected by repeated incubation with mycobacterial antigens
that mediate IL-12 production from APCs through Toll-like
receptor interactions (21). It is likely that such cells, when
derived under less biased conditions, might display a wide
range of cytokine and effector potential (22).
 
Intracellular Trafficking of CD1 Molecules
 
An important property of CD1-restricted T cells is their
inherent autoreactivity (4, 15). Different types of CD1-
restricted T cells can respond to CD1 molecules in distinct
tissue compartments, suggesting that autoantigens are ex-
pressed in different organs (17, 23). More intriguingly, the
same CD1 molecule, at least for the group II CD1d antigen,
can activate distinct classes of CD1-restricted T cells depend-
ing on its pattern of intracellular trafficking. Normally,
CD1d molecules traffic from their synthesis in the Golgi
complex to the cell surface. There, after ligation or antigen
loading, CD1 is internalized to endosomes that subsequently
acidify and eventually colocalize in the MHC class II pep-
tide-loading compartment (MIIC [24]). Internalized CD1 is
then returned to the cell surface. By mutating the tyrosine-
based amino acid motif in the CD1 tail such that the mole-
cule failed to be internalized to endosomes, Bendelac and
colleagues could indirectly assess the effects of endolysosomal
trafficking on the capacity of CD1 to activate NK T cells
(17). Unexpectedly, CD1 that had trafficked through MIIC
activated NK1
 
1
 
 V
 
a
 
14J
 
a
 
281 T cells, whereas CD1 that had
trafficked to the cell membrane from the Golgi activated
only the non-NK, non-V
 
a
 
14, CD1d-restricted T cells.
Thus, these two sets of CD1d-restricted T cells respond to
self-antigens differentially localized to cytosolic secretory or
endosomal compartments in a manner highly reminiscent of
the way in which CD8
 
1
 
 and CD4
 
1
 
 T cells respond to pep-
tides presented by class I and II antigens. With the exception
of CD1a, which does not traffic to MIIC, the other CD1
family members contain similar targeting motifs embedded
within their cytoplasmic tails.
 
Presentation of Nonpeptide Mycobacterial Ligands by Group 1 
CD1 Molecules and of Glycosylphosphatidylinositols by CD1d
 
Substantial invigoration of the field occurred with the
isolation of human T cell clones that reacted to antigens
from 
 
Mycobacterium tuberculosis
 
 and 
 
Mycobacterium leprae
 
 in a
CD1b-restricted manner (25). Antigen processing required
endosomal trafficking, but was transporter for antigen pre-
sentation (TAP) and HLA-DM independent. Several hu-
man double negative or CD8 lines and clones that reacted
in a CD1a-, 1b-, or 1c-restricted manner to various anti-
gens derived from mycobacterial cell walls, including my-
colic acid, glucose monomycolate, and lipoarabinomannan,
have been described; most generated IFN-
 
g
 
 or demon-
strated cytotoxicity upon activation (26–30). Although
most such lines expressed TCR-
 
a
 
/
 
b
 
, TCR-
 
g
 
/
 
d 
 
was also
seen. Analysis of the antigens revealed rigid requirements
for carbohydrates and other polar moieties, with the lipid
requirements being less specific. Thus, in this model, lipid
components of glucose monomycolate or lipoarabinoman-
nan would be accommodated in the large hydrophobic
cleft in CD1, positioning hydrophilic structures outwards
to enable recognition by the TCR (31).
The concept of presentation of lipid antigens via CD1 to
T cells provoked a series of experiments to find the ligand
for CD1d, the only known CD1 family member retained
in the mouse. Despite the ease with which human group 1
CD1-restricted T cells reactive to mycobacterial antigens
could be isolated in vitro, it seems clear that CD1d plays no
role in immunity to 
 
M. tuberculosis
 
 in the mouse based on
intact immunity in CD1d-deficient animals (32). Evidence 
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has been reported supporting the role of endogenous gly-
cosylphosphatidylinositol (GPI) anchors as a CD1d ligand
(33), and of parasite-derived GPI anchors in mediating
CD1d-dependent NK T cell activation for B cell help in
antibody production (34). A striking observation remains
the capacity of 
 
a
 
-galactosylceramide, a glycolipid naturally
present in sea sponges but undetectable in mammals, to ac-
tivate V
 
a
 
14- and V
 
a
 
24-bearing T cells in mice and hu-
mans, respectively (10, 35, 36). Despite only 60% identity
in the peptide-binding domains of mouse and human
CD1d, either molecule could present this ligand and acti-
vate both mouse and human NK T cells (10).
 
The Host Defense Model of CD1 Family Members
 
The presence in mice and humans of nonpolymorphic
MHC molecules that present nonpeptide antigens across
species to T cells of limited diversity that circulate with a
preprogrammed effector phenotype suggests strong evo-
lutionary pressure for their maintenance. Although the
CD1d-deficient mouse has a rather limited phenotype (37–
39), the persistence of similar types of T cells in these mice
suggests that other nonpolymorphic MHC molecules might
contribute to this pool of cells (19). The ability to demon-
strate CD1 group 1– and group 2–restricted reactivity to
mycobacterial and parasite-derived antigens, respectively,
suggests the plausible hypothesis that these lipid- and gly-
colipid-presenting molecules have been maintained to con-
fer the ability to respond to conserved cell wall determinants
from prevalent pathogens of substantial morbidity and mor-
tality. Indeed, the most prevalent 
 
g
 
/
 
d
 
 T cells in human
blood, V
 
g
 
2 and V
 
d
 
2, also recognize conserved nonpeptide
antigens from mycobacteria, e.g., prenyl pyrophosphate (40)
and phosphorylated thymidine nucleotides (41), as well as
widely distributed alkylamine compounds (42). Together,
these models envision marked evolutionary pressure from
mycobacteria and perhaps other organisms such that sub-
stantial numbers of T cells with limited diversity exist to en-
hance early immune responses to these pathogens. Before
considering some of the problems inherent in such a model,
a review of the emerging functions of other nonpolymor-
phic MHC-like molecules will be considered.
 
Nonpolymorphic MHC Molecules Participate in Diverse 
Homeostatic Functions
 
A wealth of recent data has cast new light on the role of
nonpolymorphic MHC molecules (Table I). The unex-
pected roles for several of these molecules were revealed in
 
b
 
2m-deficient mice, which are deficient not only of class I
MHC, but also of several nonpolymorphic MHC mole-
cules that rely on 
 
b
 
2m for protein stability and expression.
As reviewed below, several of these molecules demonstrate
a chaperone function for ligated “cargo” and, as with CD1,
serve as ligands for receptors on distinct populations of ef-
fector T cells (Table I). An emerging theme is the function
of these molecules to sample cellular compartments, per-
haps reflecting a role in monitoring ligands that serve as
surrogate markers indicative of cellular health.
The gene for hereditary hemochromatosis (HFE) is a
nonpolymorphic MHC molecule involved in the regula-
tion of iron metabolism. Mutation of the gene in humans is
responsible for hereditary hemochromatosis, a disorder of
iron storage that affects between 1 in 200 and 1 in 400 in-
dividuals of northern European ancestry (43). Tissue iron
overload can eventually lead to chronic liver failure, as well
as dysfunction of other organs. The crystal structure of
HFE revealed a classic MHC-like structure, although the
 
Table I.
 
Proposed Homeostatic Roles of Mouse CD1 and Other Nonpolymorphic MHC-like Molecules
 
MHC or
MHC-like
molecule
Functional
binding
groove Cargo
Recognition
by lymphocyte
receptor
Interacting ligand
and/or cell types
Proposed
homeostatic function
Classical
Class I
 
1
 
Peptide
 
1
 
CD8/TCR-
 
a
 
/
 
b 
 
T cells Host defense
Class II
 
1
 
Peptide
 
1
 
CD4/TCR-
 
a
 
/
 
b 
 
T cells Host defense
Nonpolymorphic
CD1
 
1
 
Lipid
 
1
 
CD4
 
1
 
 or DN NK, CD8
 
a
 
/
 
a
 
1
 
,
 
g
 
/
 
d
 
 T cells
Lipid membrane integrity?
H2-M3
 
1
 
Formylated peptide
 
1
 
CD4/TCR-
 
a/b T cells Mitochondrial integrity?
HLA-E (Qa-1) 1 MHC I leader peptide 1 CD94/NKG2A, B, C NK cells,
and CD81 T cells
Class I MHC expression
HLA-G 1 Peptide 1 ILT-2, p49 KIR NK and T cells Materno-fetal tolerance
MIC-A/MIC-B 2 Unknown 1 CD94/NKG2D NK, g/d T cells,
CD81 T cells
Gut epithelial integrity?
FcRn 2 IgG 1 IgG Serum Ig
ZAG Probable Lipid Unknown Unknown Lipid metabolism?
HFE 2 TfR 1 Transferrin/iron/TfR Iron910 Commentary
putative peptide-binding groove was narrowed by a trans-
lation of the a1 helix that resulted in burial of potential
peptide-binding pockets in the floor of the cleft (44). Bio-
chemical and mutational studies have defined a pathway by
which membrane HFE forms a ternary complex with iron-
bound transferrin and the transferrin receptor that assists in
the endosomal targeting of the complex (Fig. 1). A histi-
dine patch in HFE may serve to titrate a pH-dependent
dissociation of HFE from the complex within endosomes,
allowing the delivery of cellular iron. The most common
abnormalities leading to hemachromatosis are missense mu-
tations that abrogate the association of HFE with b2m, thus
destabilizing the protein.
FcRn, the neonatal Fc Ig receptor, facilitates the trans-
port of IgG from the mother’s serum across the placenta
and from the mother’s milk across the neonatal intestine.
The receptor is widely expressed on vascular endothelium
throughout life, where it participates in maintaining normal
levels of serum IgG; mice deficient in b2m and hence defi-
cient in FcRn demonstrate markedly accelerated clearance
of IgG (45). The potential peptide-binding groove in FcRn
is essentially closed, with a surface area too small (z235 Å2)
to accommodate peptides like MHC class I molecules,
which have a pocket surface area of z760 Å2 (46). Rather,
like HFE, FcRn binds IgG along the side at the interface of
the Fc CH2 and CH3 domains of Ig near a cluster of histidines
that could facilitate the pH-dependent association of the mol-
ecules, analogous to the HFE pathway (47). In adults, FcRn
may sequester endocytosed serum IgG, thus protecting it
from lysosomal degradation (Fig. 1); saturation of FcRn
may underlie the therapeutic efficacy of high-dose Ig for
autoimmune disease by accelerating the degradation of au-
toreactive antibodies (48).
CD1, in contrast to HFE and FcRn, has a large hydro-
phobic pocket that does bind ligands, and CD1 presents
ligands to specialized types of lymphocytes. In fact, both of
these properties are shared with other nonpolymorphic
MHC molecules. Of these, the molecule with a binding cleft
most similar to CD1 is zinc-a2-globulin (ZAG), which cir-
culates as a soluble serum protein. ZAG, unlike CD1, has a
network of hydrogen bonds that stabilize the molecule with-
out a requirement for b2m, but like CD1 forms a large, cen-
tral hydrophobic pocket which, although smaller than CD1,
contained a nonpeptide ligand in the crystal structure (49). In
vitro and in vivo, ZAG promotes lipolysis and fat depletion;
it was isolated as a lipid-catalyzing moiety from the urine of
cancer patients with wasting (50). Although further work is
required, evidence is consistent with a role for ZAG in me-
Figure 1. Nonpolymorphic MHC-related
molecules are involved in homeostatic
maintenance by surveying self-ligands from
distinct intracellular compartments. (A)
HLA-E presents peptides derived from the
signal sequences of class I MHC molecules
that are loaded in the endoplasmic reticulum
(ER). (B) The neonatal Fc receptor trans-
ports IgG from neonatal gut epithelium to
blood (not shown), and protects IgG catabo-
lism in adult vascular endothelium, skin,
muscle, and gut epithelium. (C) HFE binds
iron-bound transferrin on the cell surface of
gut epithelium and is trafficked through the
endosomal compartment. HFE acts as a neg-
ative modulator of transferrin receptor
(TfR)-mediated uptake of transferrin (Tf)-
bound iron, and thus plays an important role
in iron homeostasis.911 Shinkai and Locksley
diating lipid homeostasis in normal or pathologic conditions.
Concise mechanisms for regulating cellular membrane lipids
are beginning to be elucidated and are consistent with such
homeostatic processes (51).
Whereas CD1 interacts with TCR via its externally dis-
posed binding pocket, FcRn interacts with IgG or soluble
B cell receptors (BCRs) at a region distinct from its closed
cleft. Several other nonpolymorphic MHC molecules, in-
cluding H2-M3, HLA-E (Qa-1 in mouse), HLA-G, MIC-A,
and MIC-B, can interact with immune receptors on lym-
phocytes (Table I). H2-M3 is a murine class I homologue
that also forms a large surface area pocket of neutral and hy-
drophobic residues capable of accommodating peptides with
N-formylated methionine termini (52). H2-M3–restricted
CTLs that respond to formylated peptides from bacteria
have been demonstrated (2). The ability of H2-M3 to bind
endogenous formylated peptides from mitochondria would
be consistent with a primitive role in monitoring mito-
chondrial integrity, although no evidence exists for such a
function. Selection of an H2-M3–restricted TCR by one of
the endogenous 13 formylated proteins of mitochondria,
NADH dehydrogenase subunit 1, has been demonstrated
(53). Recent evidence published in this journal suggests that
preformed H2-M3 exists intracellularly and can be rapidly
mobilized to the surface when provided with an appropriate
formylated peptide ligand (54). After infection with Listeria,
the rapid accumulation of H2-M3–restricted CD81 T cells
with specificity for Listeria-derived antigens could be detected
using H2-M3 tetramer reagents (55). In contrast to conven-
tional class I– or II–restricted T cells, such cells displayed no
evidence for a memory response. Although the authors
used one mitchondrial-derived control peptide to assess
specificity, analysis with each of the self-peptide mitochon-
drial tetramers will be required to show definitively that
these T cells are not reacting to self-peptides that mediate
stress-induced rescue of intracellular H2-M3.
HLA-E in humans and Qa-1 in mice are homologous
MHC molecules that present leader sequences acquired in
the endoplasmic reticulum from MHC class I molecules in a
peptide-binding cleft at the cell surface (56). Using tetramer
technology, the ligand for HLA-E and its bound peptide
was shown to be CD94/NKG2A, B, or C, a heterodimeric,
C-type lectin superfamily receptor on NK and some T cells
that regulates NK cell activation for cytotoxicity through
association with the adaptor protein, DAP12 (57, 58). In
this way, HLA-E serves to monitor the homeostatic surface
expression of cell class I MHC molecules for surveillance by
effector lymphocytes, and thus constitutes a mechanism for
rapidly removing cells pathologically altered by several con-
ditions (Fig. 1).
The intestinal epithelial MHC-like molecules, MIC-A
and MIC-B, remarkably illustrate the preservation of this
homeostatic function despite the substantial alteration of the
underlying MHC domains. A disordering of the a2 helix
results in complete occlusion of the putative binding cleft,
and the molecules adopt an extended structure that is in-
compatible with binding by b2m (59). MIC-A and MIC-B
are induced on intestinal cells by stress-activatible promot-
ers, where they are recognized by Vd1-expressing g/d T
cells that occupy subepithelial locations in the intestine (60).
Diverse nonhuman primate MIC molecules activate cyto-
toxicity by human Vd1 T cell clones, consistent with rec-
ognition of a conserved surface on the side of MIC mole-
cules near the footprint occupied by b2m in class I MHC.
Despite interaction at a domain distinct from the residual
binding pocket, MIC molecules, like HLA-E, interact with
C-type lectin NK receptors, NKG2D expressed on Vd1 T
cells, NK cells, and some CD81 T cells (61). Activation of
the lymphocytes occurs through association of NKG2D
with an activating adaptor protein, DAP10, resulting in cell
death of the MIC-bearing target (62). Although its biologi-
cal function remains unknown, MIC molecules likely play a
role in monitoring intestinal epithelial integrity. Indeed, the
turnover of epithelial cells in intestinal villi is substantially
reduced in g/d-deficient mice (63).
A Reevaluation of CD1
As shown by the above examples, the capacity to bind
ligands, including lipids, and to interact with relatively in-
variant lymphocyte receptors are properties of CD1 shared
by other nonpolymorphic MHC molecules (Table I). Fre-
quently, T cells restricted by nonpolymorphic MHC are lo-
calized to distinct tissue compartments. Examples include
NK T cells in the liver, and MIC-A– and MIC-B–restricted
T cells and (as most recently described in this journal)
CD8a/a intraepithelial T cells in the intestine (64, 65).
The restricted expression of HLA-G in the placenta may
represent yet another example suggesting a specialized ho-
meostatic function for these invariant molecules in survey-
ing placental integrity (66). These considerations suggest
that these various properties were evolutionarily endowed
upon CD1 before the appearance of mycobacterial human
pathogens. The concept that CD1 remains “hard-wired” in
order to confront M. tuberculosis or M. leprae is difficult to
conceptualize, given the biology of these organisms. First,
M. tuberculosis has probably existed as a human pathogen
only since the domestication of cattle some 7,500 years ago,
presumably reflecting a transspecies adaptation by Mycobacte-
rium bovis. Second, both M. tuberculosis and M. leprae, al-
though undeniably of immense public health concern, cause
disease in only a minority of persons infected during their re-
productive life spans. Third, although the group 1 CD1 pro-
teins can present antigens from M. tuberculosis, mice, which
are inherently more resistant to tuberculosis than humans,
have deleted the group 1 CD1 genes, whereas guinea pigs,
which have expanded numbers of these genes, are extraordi-
narily susceptible to tuberculosis (4). Finally, the ubiquitous
environmental mycobacteria are relatively nonpathogenic
organisms that require marked deficiencies in the adaptive
immune system, e.g., advanced HIV infection or genetic de-
letions of the IL-12, IL-12R, or IFN-gR genes (67), to cause
disease. The likelihood that the evolutionary impetus for
CD1 derived from these organisms seems remote.
The sequencing of the M. tuberculosis genome offers ex-
traordinary insights regarding the biology of this organism
(68). Compared with Escherichia coli, which has only 50 genes912 Commentary
devoted to fatty acid metabolism, M. tuberculosis has .250
distinct enzymes involved in the synthesis and catabolism of
a diverse array of lipophilic molecules. Mycobacteria contain
enzymes representing all of the classes of lipid and polyketide
biosynthesis normally found in mammals, plants, and bacte-
ria. It seems likely that mycobacteria infection would result
in substantial effects on endogenous lipid metabolism of the
cell. If CD1 molecules were normally loaded with an endog-
enous cell-derived lipid, as suggested by the autoreactive na-
ture of NK T cells (4, 15) or the Vg2/Vd1 T cells isolated by
Spada et al. (5), it is likely that disruption of normal lipid syn-
thetic pathways could alter the distribution or amount of the
endogenous CD1 ligand. As such, CD1 function would
more closely resemble that of other nonpolymorphic MHC
molecules in providing information regarding deviation from
normal cellular biosynthetic pathways, perhaps relating to
lipid membrane homeostasis (Table I). In this model, myco-
bacteria have evolved to displace or induce the normal
CD1-associated ligand. But why would M. tuberculosis have
evolved to activate CD1-restricted T cells?
M. tuberculosis is unusual because of its airborne transmis-
sibility. In contrast, most bacteria that cause pneumonia do
so after establishing colonization in the pharynx, from
which microaspiration can occur and cause disease in the
appropriate host and clinical setting. Airborne transmission
relies on the discharge of enormous numbers of bacilli,
usually by coughing. The pathology of tuberculosis is
marked by an inflammatory granulomatous response that
results in sequestration of organisms within areas of lique-
faction and tissue destruction, termed caseous necrosis. It is
in these caseous areas that organisms remain viable for
years, awaiting periods of diminished immunity that will al-
low reactivation of dormant bacilli. The capacity of myco-
bacteria to elicit strong inflammatory responses—the adju-
vant in Freund’s adjuvant—may be critical in inducing
sufficient tissue destruction to facilitate passage of organisms
to the airspaces, where triggering of cough and transmis-
sion to the environment can occur. It is likely that myco-
bacteria have exploited the inherent effector capacity of
NK and related T cells, and perhaps g/d T cells, to engen-
der the granulomatous inflammatory response that ensures
both longevity in the host and eventual transmission to
others. Recent experiments suggest such contributions from
NK T cells (69). By this hypothesis, M. tuberculosis exploits
the effector potential and ligand recognition properties of
CD1, which have evolved for unrelated housekeeping
functions, to ensure its survival and transmission, consistent
with the capacity of this organism to have infected up to
one third of the human population on earth.
On the Origin of Class I and Class II MHC
Taken together, we would speculate that it is the ability
to present, either through recognition of the molecule itself
or of its chaperoned cargo, information regarding the gen-
eral baseline health of the cell that unites the function of
these diverse MHC molecules. Frequently, this involves
trafficking through distinct cellular compartments that al-
low dynamic interactions with their various ligands. This,
of course, is exactly the function of class I and class II MHC,
which display peptide ligands acquired from different cell
compartments for surveillance by lymphocytes. However,
for these molecules, the capture of bacterial transposases al-
lowed the unlimited rearrangements of the scanning recep-
tors, establishing the capacity to monitor cellular homeostasis
with unprecedented precision. Of importance is the presence
of these surveillance detectors on lymphocytes, cells capable
of clonal expansion, thus enabling the amplification of highly
specific effector programs. Again, evolutionary precedents es-
tablished by the nonpolymorphic MHC molecules have
identified a preexisting relationship, whereby lymphocytes
survey these types of molecules to unleash effector pathways
involved in monitoring tissue health and integrity. It is in-
triguing to speculate that some primordial footprint of the
evolutionary role of class I and class II MHC might remain
that is independent of the widely accepted role of these mole-
cules in adaptive immunity.
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